Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report

RATIONALE: Regorafenib is an oral multikinase inhibitor and is approved as salvage therapy in the standard treatment of advanced colorectal cancer (CRC). Due to its limited efficacy, toxicity profile, and cost, it is necessary to identify those patients who may have the most benefit from regorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosati, Gerardo, Del Gaudio, Nunzio, Scarano, Enrico, Cifarelli, Rosa Anna, Altucci, Lucia, Bilancia, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023677/
https://www.ncbi.nlm.nih.gov/pubmed/29924031
http://dx.doi.org/10.1097/MD.0000000000011178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023677/
https://www.ncbi.nlm.nih.gov/pubmed/29924031
http://dx.doi.org/10.1097/MD.0000000000011178

Ejemplares similares